Abstract submission deadline: August 5, 2019
Meeting registration deadline: September 30, 2019
Selected Confirmed Keynote Speakers
University of Granada, Spain
Prof. Antonio Campos is a full-professor of the Histology Department in the University of Granada in Spain and the director of the Tissue Engineering Group of this University. He has held the following positions: President of the Spanish Society of Histology (1983-1993), Dean of the Faculty of Medicine of Granada (1992-2000), President of the Spanish Conference of Medical Schools (1996-2000), President of the European Association of Faculties of Medicine (2000-2001), Representative of Spain in the Consultative Committee of the European Union for the Training of Physicians (1998), Advisory Board Member of Science and Technology (2000-2004), Director of the National Institute of Health Carlos III (2000-2004), Member of Editorial Boards and Scientific Evaluator in journals and national and international institutions, Member of the Royal National Academy of Medicine (since 2004) and Honoris Causa degree for Cordoba National University in Argentina, Autonomous University of Santo Domingo, in Dominican Republic (first university founded in America) and the Aveiro University in Portugal. Moreover, he has published relevant books and papers in high impact factor journals related to tissue engineering and also Medical Education. His group has generated several artificial tissues by tissue engineering that are presently being applied or in clinical trial.
Michele De Luca
University of Modena, Italy
Michele De Luca, MD, is Director of the Centre for Regenerative Medicine “Stefano Ferrari” and the Interdepartmental Centre for Stem Cells and Regenerative Medicine at the University of Modena and Reggio Emilia and Scientific Director and co-founder of the university spin-off Holostem Terapie Avanzate.
De Luca was Scientific Director of Veneto Eye Bank Foundation in Venice (2000-2007) and Head of Laboratory of Tissue Engineering at Istituto Dermopatico dell’Immacolata in Rome (1996-2002), Deputy Head (1992-1995) and Senior Investigator (1986-1992) at Laboratory of Stem Cell Differentiation at National Institute for Cancer Research in Genova, Visiting scientist at the Department of Physiology and Biophysics of Harvard Medical School in Boston (1985) and Fogarty Fellow at the NIH (NIADDK) in Bethesda (1982-1985).
De Luca is author of over 120 peer reviewed international publications, has been invited speaker in approximately 200 international meetings worldwide. He is internationally recognized as a leading scientist in epithelial stem cell biology aimed at clinical application in regenerative medicine and played a pivotal role in epithelial stem cell-mediated cell and gene therapy.
Tel Aviv University, Tissue Engineering and RegMed, Israel
Tal Dvir is a Professor at Tel Aviv University, Israel. He obtained his B.Sc. (2003) and Ph.D (2008) degrees from the faculty of Engineering at Ben-Gurion University of the Negev in Israel. His Ph.D research focused on cardiac tissue engineering and regeneration. Tal continued his postdoctoral studies in the laboratory of Prof. Robert Langer in the Department of Chemical Engineering at MIT. His postdoc research focused on advanced materials for tissue engineering and regeneration.
On October 2011 Tal was recruited by the Department of Biotechnology and the Center for Nanotechnology at Tel Aviv University to establish the Laboratory for Tissue Engineering and Regenerative Medicine. On 2013, Tal has also joined the newly established Department of Materials Science and Engineering at Tel Aviv. Since 2017, Tal is the founding director of the Sagol Center for Regenerative Biotechnology.
Currently, Tal’s laboratory designs and develops smart bio and nanomaterials and technologies for engineering complex tissues, such as the heart, brain, spinal cord, intestine, eyes and more.
Tal has published many papers in top journals and received numerous awards, including the Rappaport prize and the Juludan prize.
University of Trento, Italy
Antonella Motta is Associate professor at Department of Industrial Engineering, University of Trento, Italy. Graduated in Natural Sciences at the University of Padova (Italy), with PhD in Biomaterials by University of Trento (Italy). The research topics include engineered polymer-based materials for regenerative medicine applications, chemical-physical and biological characterization of materials for biomedical use, interactions between implants materials, proteins and cells, protein based materials, immobilization and adhesion mechanisms of proteins and cells, blood-contacting materials, nanostructured materials for biomedical applications; in particular, a 20 years experience on silk-based matrices design for application in tissue engineering and 3D in vitro models.
Co-Editor-in-Chief of Journal of Biomaterials, Polymer Edition; Associate Editor of Journal of Bioactive and Compatible Polymers; Member of the Scientific Editorial Board of International Journals, and referee for international Journals in the Biomaterials and Biomedical Technologies field.
Visiting professor in several Universities, i.e. Tufts University (MA, USA), Chulalongkorn University (Bangkok, Thailand), University of Texas at Arlington (TX, USA), University of Colorado at Boulder (CO, USA).
About 160 publications in International Journals, Co-editor of a book on Tissue engineering, 9 book chapters, 8 International Patents. Invited Speaker at several International and National Conferences and Schools.
Pediatrics-Hem-Onc Cell & Gene, Baylor College of Medicine, Houston, TX, US
Cliona Rooney, PhD, is a Professor in the Center for Cell and Gene Therapy (CAGT) and in the Departments of Pediatrics, Molecular Virology, and Immunology at Baylor College of Medicine and the Director of the Translational Research Laboratories of the CAGT. Her scientific training is in viral immunology and since 1992 she has used virus-specific T-cells (VSTs) for the treatment of virus-associated diseases and malignancies. She first used EBV-specific T-cells to prevention and treat the EBV+ post-transplant lymphoma, then extended this successful therapy to other post-transplant viral infections, and to EBV+ malignancies that occur in immunocompetent individuals. She is clinically evaluating strategies that render T cells resistant to inhibition by the tumor microenvironment, such as a dominant-negative TGF-beta receptor and a constitutively active IL-7 receptor. She developed an inducible caspase 9 suicide gene that has proved successful in clinical trials. To overcome the lack of in vivo proliferation of tumor-specific T-cells, she has evaluated VSTs as hosts for CARs, so that CAR-VST activation and expansion can be induced by endogenous viruses, viral vaccines or oncolytic viruses. She has been a PI on over 20 clinical protocols involving cellular therapies and co-investigator on over 40. She is a founder member of Marker Therapeutics and AlloVir, is on the scientific advisory board of CellGenix and is the author of over 300 scientific publications.
University of California, San Francisco, CA, US
Eric Shifrut is currently a senior postdoctoral fellow at UCSF working with Dr. Alexander Marson. Eric completed his PhD at the Weizmann Institute of Science in Israel, under supervision of Prof. Nir Friedman. In his thesis work, Eric developed computational and experimental platforms to map the landscape of T cell receptor repertoires in health and disease. Since joining the Marson lab in 2016, Eric has been working to pioneer CRISPR applications in primary human T cells. These efforts aim to design discovery platforms to explore and exploit genetic circuits to boost T cell function in cancer immunotherapy. His research focuses on engineering human T cell therapies with an enhanced ability to survive in the suppressive tumor microenvironment.
Eric is a co-author of multiple patents in T cell engineering and his work has generated more than 750 citations. He serves as a scientific consultant to cell therapy companies and has been an invited speaker at several international scientific meetings. He continues to develop new experimental platforms and computational frameworks to pursue key questions in adaptive immunity, immune tolerance and engineered cell therapies.
Weizmann Institute of Science, Israel
Ada Yonath focuses on genetic code translation by ribosomes, on antibiotics paralyzing this process, on designing novel antibiotics for resistant pathogenic bacteria and on origin of life. She graduated from Hebrew University, earned PhD from Weizmann Institute (WIS) and completed postdoctoral studies at CMU and MIT, USA. In 1971 she established the first biological-crystallography laboratory in Israel, which was the only lab of this kind in the country for almost a decade and became a WIS faculty member. Since 1989 she is the Director of Kimmelman Center for Biomolecular Structures at WIS. In 1978-9 she spent a Sabbatical in Chicago U, and during 1980-2004 in parallel to her WIS activities, she headed the Max-Planck-Research-Unit for Ribosome Structure in DESY, Hamburg.
Among others, she is a member of US National Academy of Sciences (NAS); Israel Academy of Sciences & Humanities; German Academy for Sciences; European Molecular Biology Organization; Pontifical Academy of Sciences; International Academy of Astronautics; Accademia Nazionale dei Lincei, Rome; and Royal European Academy of Doctors (RAED).
She holds honorary doctorates from over 20 universities worldwide, in Israel, USA, Latin America, Europe and the Far East. Her awards include the Israel Prize; Linus Pauling Gold Medal; Albert Einstein World Award for Excellence; UNESCO-L’Oréal Award; the Wolf Prize; the Golden DESY Pin; the Paul Ehrlich Medal; the Erice Peace Prize and the Nobel Prize for Chemistry.
University of Minho, Portugal
University of Minho, Portugal
Please come back visit this section to find more information about the selected speakers.
Additional keynote speakers in the field of Advanced Therapies are approached and will be announced when confirmed.